Locations
San Francisco, CA, USA
industry
Biotechnology · DeepTech · Health · Information Technology
Size
11-50 employees
Stage
Seed
founded in
2018
Immune Bridge is developing a new generation of allogeneic cell therapies to make cancer cures accessible to everyone. Their proprietary expansion technology amplifies cord blood-derived immune stem cells while maintaining full immune multipotency, creating a diverse and abundant cellular source for immunotherapies. The company is focused on natural killer (NK) cell-based immunotherapies, aiming to bridge the gap between innate cellular capabilities and modern engineering to provide safe and effective treatments for cancer patients. Founded in 2018 and based in the San Francisco Bay Area, Immune Bridge is committed to scaling cell therapy and saving lives faster through innovative collaborations and technology.
Something looks off?